TransMedics Group Inc. (TMDX)
NASDAQ: TMDX
· Real-Time Price · USD
114.56
-2.43 (-2.08%)
At close: Sep 12, 2025, 3:59 PM
114.64
0.07%
After-hours: Sep 12, 2025, 04:47 PM EDT
-2.08% (1D)
| Bid | 114.5 |
| Market Cap | 3.91B |
| Revenue (ttm) | 531.29M |
| Net Income (ttm) | 71.66M |
| EPS (ttm) | 1.99 |
| PE Ratio (ttm) | 57.57 |
| Forward PE | 39.34 |
| Analyst | Buy |
| Ask | 116.94 |
| Volume | 785,691 |
| Avg. Volume (20D) | 1,187,792.8 |
| Open | 115.38 |
| Previous Close | 116.99 |
| Day's Range | 112.50 - 116.39 |
| 52-Week Range | 55.00 - 169.29 |
| Beta | 2.17 |
About TMDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TMDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TMDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
TransMedics Group Inc. is scheduled to release its earnings on
Oct 27, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+11.14%
TransMedics shares are trading higher following a ...
Unlock content with
Pro Subscription
1 month ago
+6.59%
TransMedics Group shares are trading higher after the company announced it has been granted FDA IDE conditional approval.
2 weeks ago · seekingalpha.com
TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3TransMedics delivered another strong beat-and-raise quarter, but Q3 faces a likely seasonal slowdown that could disappoint optimistic investors. The long-term thesis remains robust: best-in-class pres...
